News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>M Stanley Bullish on CN Pharma Sector, Raising TPs for HANSOH PHARMA, Others
Morgan Stanley has issued a research report expressing an optimistic outlook for China's pharma industry in light of a series of favorable domestic policies like comprehensive ...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley Bullish on CN Pharma Sector, Raising TPs for HANSOH PHARMA, Others
Close
Recommend
29
Positive
45
Negative
23
 
SHORT SELL
 
STOCK INFO

Morgan Stanley has issued a research report expressing an optimistic outlook for China's pharma industry in light of a series of favorable domestic policies like comprehensive support for innovation.

In addition, most Chinese pharma companies have low reliance on exports to the US, making the sector relatively less vulnerable to geopolitical tensions and uncertainties in US drug pricing.

While legacy drugs will continue to weigh on the short-term growth of many companies and make only minimal contribution, Morgan Stanley pointed out that their gradual exit can make investors reassess the value and catalysts of companies' product pipelines.

Morgan Stanley raised its target price for HANSOH PHARMA (03692.HK)  +0.500 (+2.012%)    Short selling $49.19M; Ratio 32.558%   from HKD25 to HKD29 and kept the Overweight rating unchanged due to its high-quality product portfolio and robust growth prospects.

The target price for SINO BIOPHARM (01177.HK)  +0.030 (+0.718%)    Short selling $47.71M; Ratio 34.515%   was lifted from HKD4.6 to HKD4.9 with an Overweight rating maintained because of its industry-leading growth and a wealth of catalysts expected this year.

The broker also added its target price for CSPC PHARMA (01093.HK)  +0.250 (+3.968%)    Short selling $277.80M; Ratio 31.710%   from HKD6.7 to HKD6.8 as its pipeline was undervalued. It gave the company an Overweight rating.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-21 12:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.